Keywords: amgen, pantiumumab, sees, strong, ph, iii, data

Amgen's pantiumumab sees strong Ph III data

Article | 17 April 2006

Print This

USA-based biotechnology major Amgen saw encouraging Phase III results on its cancer drug panitumumab presented at the 2006 annual meeting of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in